Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
Tornin J, Hermida-Prado F, Padda RS, Gonzalez MV, Alvarez-Fernandez C, Rey V, Martinez-Cruzado L, Estupiñan O, Menendez ST, Fernandez-Nevado L, Astudillo A, Rodrigo JP, Lucien F, Kim Y, Leong HS, Garcia-Pedrero JM, Rodriguez R. Tornin J, et al. Neoplasia. 2018 Jan;20(1):44-56. doi: 10.1016/j.neo.2017.11.004. Epub 2017 Nov 28. Neoplasia. 2018. PMID: 29190494 Free PMC article.
The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas.
Estupiñan O, Santos L, Rodriguez A, Fernandez-Nevado L, Costales P, Perez-Escuredo J, Hermosilla MA, Oro P, Rey V, Tornin J, Allonca E, Fernandez-Garcia MT, Alvarez-Fernandez C, Braña A, Astudillo A, Menendez ST, Moris F, Rodriguez R. Estupiñan O, et al. Int J Cancer. 2019 Jul 1;145(1):254-266. doi: 10.1002/ijc.32081. Epub 2019 Jan 14. Int J Cancer. 2019. PMID: 30575954 Free article.
Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC).
Alvarez-Fernandez C, Perez-Arnillas Q, Ruiz-Echeverria L, Rodriguez-Rubi D, Sanchez-Lorenzo L, Li-Torres W, Izquierdo-Manuel M, Berros JP, Luque-Cabal M, Jimenez-Fonseca P, Villanueva-Palicio N, Esteban-Gonzalez E. Alvarez-Fernandez C, et al. Invest New Drugs. 2014 Apr;32(2):377-81. doi: 10.1007/s10637-013-9992-1. Epub 2013 Aug 4. Invest New Drugs. 2014. PMID: 23912258
Benefit of on nephrectomy for treating metastatic renal cell carcinoma.
González-Ruiz de León C, Pellejero-Pérez P, Quintás-Blanco A, García-Rodríguez J, Álvarez-Fernández C, Fernández-Gómez JM. González-Ruiz de León C, et al. Actas Urol Esp. 2017 Jun;41(5):338-342. doi: 10.1016/j.acuro.2016.10.004. Epub 2017 Jan 13. Actas Urol Esp. 2017. PMID: 28094071 English, Spanish.
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, García-Donas J, González Rodríguez M, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuéllar-Rivas MA, Rodríguez-Alonso RM, Rodríguez-Moreno JF, Suarez-Rodriguez C. Grande E, et al. ESMO Open. 2022 Apr;7(2):100463. doi: 10.1016/j.esmoop.2022.100463. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405437 Free PMC article. Clinical Trial.
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group.
García-Del-Muro X, Durán I, Perez-Gracia JL, Ángel Climent M, Mellado B, Virizuela JA, Castellano DE, González Del Alba A, García Carbonero I, Álvarez-Fernández C, García-Donas J, Gil-Martin M, Hernández AG. García-Del-Muro X, et al. Clin Genitourin Cancer. 2022 Aug;20(4):388.e1-388.e10. doi: 10.1016/j.clgc.2022.03.008. Epub 2022 Mar 18. Clin Genitourin Cancer. 2022. PMID: 35428584 Clinical Trial.
47 results